Risk for Ventricular Fibrillation in Peripartum Cardiomyopathy with Severely Reduced Left Ventricular Function—Value of the Wearable Cardioverter/Defibrillator
Why the study?
Does the use of a wearable cardioverter/defibrillator (WCD) prevent sudden cardiac death from ventricular tachyarrhythmias in women with early peripartum cardiomyopathy and severely reduced LVEF?
Population
12 consecutively admitted women with early peripartum cardiomyopathy and symptoms of heart failure…
Comparison
Wearable cardioverter/defibrillator for 3 to 6… vs No WCD (2 patients refused to wear a WCD).
Design
Cohort
Follow-up
Median WCD follow-up of 81 days; overall median follow-up…
Authors
Discussion
Loading...
Member takes
Implication
Supports WCD as potential bridge in peripartum cardiomyopathy with low LVEF; hypothesis-generating, needs randomized confirmation before practice change.
Structured PICO
Does the use of a wearable cardioverter/defibrillator (WCD) prevent sudden cardiac death from ventricular tachyarrhythmias in women with early peripartum cardiomyopathy and severely reduced LVEF?
P
Population
12 consecutively admitted women with early peripartum cardiomyopathy (PPCM) and symptoms of heart failure, including 9 with severely reduced LVEF (mean 18.3%).
I
Intervention
Wearable cardioverter/defibrillator (WCD) for 3 to 6 months.
C
Comparator
No WCD (2 patients refused to wear a WCD).
O
Outcome
Ventricular fibrillation events and appropriate WCD shocks.hard clinical
In women with early peripartum cardiomyopathy and severely reduced LVEF, a wearable cardioverter/defibrillator successfully treated life-threatening ventricular fibrillation in a high proportion of patients, suggesting its value as a bridge to LVEF recovery.
Cite This Study
Duncker et al. (2014) studied this question.